GSA Capital Partners LLP Invests $136,000 in Sight Sciences, Inc. (NASDAQ:SGHT)

GSA Capital Partners LLP acquired a new stake in Sight Sciences, Inc. (NASDAQ:SGHT) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 21,514 shares of the company’s stock, valued at approximately $136,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. boosted its position in Sight Sciences by 25.5% during the first quarter. Jacobs Levy Equity Management Inc. now owns 377,057 shares of the company’s stock valued at $1,991,000 after buying an additional 76,549 shares during the period. Vanguard Group Inc. boosted its holdings in Sight Sciences by 5.5% during the 1st quarter. Vanguard Group Inc. now owns 1,556,450 shares of the company’s stock valued at $8,218,000 after acquiring an additional 81,768 shares during the period. Acadian Asset Management LLC grew its position in Sight Sciences by 256.6% during the 2nd quarter. Acadian Asset Management LLC now owns 83,693 shares of the company’s stock worth $556,000 after acquiring an additional 60,220 shares during the last quarter. Long Focus Capital Management LLC increased its stake in Sight Sciences by 86.9% in the 2nd quarter. Long Focus Capital Management LLC now owns 560,594 shares of the company’s stock worth $3,739,000 after purchasing an additional 260,594 shares during the period. Finally, State Board of Administration of Florida Retirement System bought a new stake in Sight Sciences in the first quarter valued at approximately $59,000. Institutional investors own 55.51% of the company’s stock.

Insider Transactions at Sight Sciences

In other news, CEO Paul Badawi sold 12,727 shares of Sight Sciences stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $5.99, for a total transaction of $76,234.73. Following the transaction, the chief executive officer now owns 5,725,433 shares in the company, valued at $34,295,343.67. This trade represents a 0.22 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Matthew Link sold 21,831 shares of the company’s stock in a transaction on Monday, October 21st. The stock was sold at an average price of $5.61, for a total value of $122,471.91. Following the completion of the sale, the insider now owns 663,550 shares of the company’s stock, valued at $3,722,515.50. This trade represents a 3.19 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 97,357 shares of company stock worth $574,666 in the last ninety days. Insiders own 28.90% of the company’s stock.

Sight Sciences Trading Down 0.7 %

Sight Sciences stock opened at $3.98 on Tuesday. The company has a debt-to-equity ratio of 0.36, a current ratio of 10.18 and a quick ratio of 9.74. The stock has a market capitalization of $202.02 million, a PE ratio of -3.90 and a beta of 2.74. The business’s fifty day moving average is $5.36 and its 200 day moving average is $6.12. Sight Sciences, Inc. has a one year low of $2.58 and a one year high of $8.45.

Sight Sciences (NASDAQ:SGHT) last issued its quarterly earnings data on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.01. Sight Sciences had a negative net margin of 63.30% and a negative return on equity of 47.28%. The company had revenue of $20.16 million for the quarter, compared to the consensus estimate of $20.41 million. On average, sell-side analysts predict that Sight Sciences, Inc. will post -1.01 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently commented on SGHT. Morgan Stanley decreased their target price on shares of Sight Sciences from $7.00 to $5.00 and set an “equal weight” rating on the stock in a research note on Monday, November 11th. Lake Street Capital lowered shares of Sight Sciences from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $10.00 to $5.00 in a report on Monday, November 4th. Piper Sandler reaffirmed a “neutral” rating and issued a $5.50 target price (down from $6.00) on shares of Sight Sciences in a research report on Friday, November 8th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Friday, November 8th. Five equities research analysts have rated the stock with a hold rating, According to MarketBeat.com, Sight Sciences currently has a consensus rating of “Hold” and an average price target of $5.50.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.